Teva Pharmaceutical Industries Ltd (XBUL:TEV)
лв 15.85 0 (0%) Market Cap: 17.96 Bil Enterprise Value: 48.53 Bil PE Ratio: 0 PB Ratio: 4.12 GF Score: 44/100

Teva Pharmaceutical Industries Ltd at JPMorgan Healthcare Conference Transcript

Jan 08, 2024 / 04:15PM GMT
Christopher Thomas Schott
JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning, everybody. I'm Chris Schott, pharma analyst at JPMorgan. And it's my pleasure to be introducing Teva today.

From the company we have CEO, Richard Francis. Richard joined Teva roughly a year ago. The company has had a very productive 2023 and looking forward to hearing about the setup for Teva going forward.

So with that, Richard, thanks for joining us. And we'll jump to Q&A after your presentation.

Richard D. Francis
Teva Pharmaceutical Industries Limited - President, CEO & Director

Thanks very much, Chris. Good morning, everybody. Delighted to be here. Yes, it's been One year, one hell of a year, where I think that the work we've done at Teva has really transformed Teva, quite a bit of change and put us on the path for continuous growth going forward. So very excited about that.

And let me walk you through a bit of what's given me that optimism and some of the progress we've made in that first year. So when I was here last

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot